Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07645924 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 114 to 113 Eligibility criteria expanded, about 75 wordsv8 Show 1 more changeShow less
    • Eligibility criteria expanded, about 75 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 115 to 114v7
  3. Start date changed from estimate of Jul 2026 to Jul 1, 2026 Site details revised at 34 of 115 sitesv6 Show 1 more changeShow less
    • Site details revised at 34 of 115 sites
  4. Site details revised at 21 of 115 sitesv5
  5. Site details revised at 4 of 115 sitesv4
  6. Site details revised at 22 of 115 sitesv3
  7. Recruitment opened Trial sites reduced: 120 → 115 locationsv2 Show 1 more changeShow less
    • Trial sites reduced: 120 → 115 locations
  8. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kallyope Inc.
4 trials monitored
See all monitored trials
Migraine
467 trials monitored
See 24 trials at risk
This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.
Trial Details
NCT Number NCT07645924
Lead Sponsor Kallyope Inc.
Conditions Migraine
Enrollment 1,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov